PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))

Core Insights - PharmaTher Holdings Ltd. has received FDA approval for its ketamine product KETARx™ for surgical pain management, marking a significant milestone for the company [2][3] - The approval is seen as a turning point for PharmaTher, opening up new opportunities for the company and benefiting millions of patients in need [3][10] - The company is moving quickly into pre-launch commercialization of KETARx™ in the U.S. and preparing for international regulatory filings [4][5] Commercialization Strategy - PharmaTher is advancing its commercial plan to launch KETARx™ this year, targeting hospitals, specialty clinics, and government institutions [5] - Partnership discussions with specialty pharmaceutical companies are already underway, indicating strong interest in KETARx™ [4][5] - The company aims to create a scalable sales channel and support clinical research programs and special access programs [5] Future Potential - The long-term potential for KETARx™ extends beyond surgical pain management, with opportunities in other indications such as mental health and neurological disorders [6][9] - The company is focused on unlocking the full pharmaceutical potential of ketamine, with ongoing clinical-stage programs for conditions like Parkinson's disease and ALS [7][8] - The current regulatory environment is favorable for psychedelic-assisted therapies, which may enhance the prospects for ketamine innovation [9] Vision and Commitment - PharmaTher's vision since its founding in 2020 has been to fully leverage ketamine's therapeutic potential, culminating in the recent FDA approval [10] - The company is committed to innovating and expanding globally, aiming to become a leader in next-generation ketamine therapeutics [11][12] - The CEO expresses confidence in the company's ability to create meaningful impacts for patients and unlock the full potential of ketamine [12]